Drug Type Bispecific antibody |
Synonyms SRB 22, SRB22 |
Target |
Action antagonists, inhibitors |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists), TRAIL inhibitors(Tumor necrosis factor ligand superfamily member 10 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | Chile | 10 Oct 2022 |






